Latest Feature

Wound care by the numbers: Q&A with Alliqua CEO Dave Johnson

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

Podcast: Medtech legends and leaders on the state of medical device innovation brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.

CardioMEMS took 11 years to pay off, but for Boston Millennia it was worth it

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

Podcast: Haemonetics CEO Brian Concannon at's DeviceTalks

Haemonetics CEO Brian Concannon discusses how the company will transform blood management in the coming years at's DeviceTalks Boston event.

Calhoun Vision aims to disrupt ophthalmology with its light-adjustable lens

Calhoun Vision CEO Verne Sharma tells why his company's light-adjustable lens will disrupt the practice of ophthalmology.

Subscribe to the MassDevice
Enter your email:

Need Medtech news in a minute? We Deliver!

MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

Covidien snaps up Reverse Medical

August 22, 2014 by Brad Perriello

Covidien snaps up Reverse Medical and its line of vascular devices for an unspecified amount.


Second Sight Medical lands French funding for 'bionic eye'

August 22, 2014 by Arezu Sarvestani

The French Ministry of Health offers to provide financial support to treat 36 patients with Second Sight Medical's Argus II retinal prosthesis system.

Second Sight Medical lands reimbursement in France

Second Sight Medical announced this week that it landed a financial contract with the French Ministry of Health to provide funding for the 1st wave of patients in the country to receive treatment with the Argus II vision system.

Medtech tax slip-up fuels calls for repeal | On Call

August 22, 2014 by Arezu Sarvestani

Opponents of the medical device tax have new grounds for their calls for repeal after a U.S. Treasury report finds that the IRS is having a hard time making sense of the levy. On Call

MASSDEVICE ON CALL — Medical device industry lobbyists have new ammunition in the fight against the 2.3% Affordable Care Act tax thanks to a U.S. Treasury report citing several issues with the IRS's management of the levy.

Report: Medtronic butts heads with shareholders at annual meeting

August 22, 2014 by Arezu Sarvestani

Some of Medtronic's shareholders aren't pleased about the structure of the $43 billion mega-merger with Covidien, which will stick some long-time backers with significant fees.

Report: Medtronic butts heads with shareholders at annual meeting +3 | The top 3 medtech stories for August 21, 2014

August 21, 2014 by MassDevice

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.


Nobel Biocare's Q2 profits double as it fields buyout interest

August 21, 2014 by Brad Perriello

Nobel Biocare doubles its 2nd-quarter profits as it reportedly fields interest – and at least 1 offer worth $2.3 billion – from potential acquirers.

Nobel Biocare's Q2 profits double as it fields buyout interest

Claret Medical chases FDA win with $18M Series B for cerebral protection device

August 21, 2014 by Arezu Sarvestani

California device maker Claret Medical plans to use its new funds to complete a U.S. pivotal trial of its Sentinel cerebral protection system.

Claret Medical chases FDA win with up to $18M raised in Series B

Claret Medical said today that it secured up to $18 million in Series B financing it plans to use to make progress toward the U.S. market.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp